Bacteriophages and AMR, the beginning of a new era?

The newly published EMA draft guideline on the quality aspects of phage therapy medicinal products paves the way for the use in Western Europe of this new - albeit century-old - approach to treating antibiotic-resistant infections

The UK’s new decentralised manufacturing framework

The new Decentralised Manufacturing Framework came into force on 23 July 2025. It enables the production of innovative medicines products such as cellular therapies close to the patients who will receive them. The framework covers both Point of Care manufacturing and Modular Manufacturing, and it requires prior authorisation and provides an alternative to traditional, centralised productions

The challenging roadmap to design the future of EU’s R&D

The ongoing debate on simplifying and standardising the rules for accessing EU research funding is in an hot phase. ERC president Maria Leptin rejected the Commission’s proposals, while the ERC Scientific Council published its new rules for the evaluation of scientific proposals. In a recent speech on the advancement of the Competitiveness Compass, Mario Draghi emphasised the need for a more proactive approach to priority programmes on critical technologies. He also drew attention to dual-use technologies, an approach combining civil and defence applications which has divided the EU Parliament

Consultation open on the revision of GMP’s Chapter 1

Comments on the draft revision of Chapter 1 of the Good Manufacturing Practices must be submitted by 3 December 2025. The revision aims to update this fundamental text in light of the more recent advancements in pharmaceutical manufacturing, so to better ensure the ef-fectiveness and safety of medicinal products. The EIPG will liaise with member associations to submit a joint response to the draft text.